Get the Stockscreener App
10.86
0.09%
-0.010
After Hours:
10.86
Fulcrum Therapeutics Inc stock is traded at $10.86, with a volume of 462.48K.
It is down -0.09% in the last 24 hours and up +14.20% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$10.87
Open:
$10.88
24h Volume:
462.48K
Relative Volume:
0.35
Market Cap:
$716.44M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-6.8734
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
+13.72%
1M Performance:
+14.20%
6M Performance:
+66.06%
1Y Performance:
+205.06%
1-Day Range:
$10.46
$11.09
1-Week Range:
$9.37
$11.09
52-Week Range:
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
10.86 | 717.10M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | JP Morgan | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? - Finviz
Fulcrum Therapeutics (NASDAQ:FULC) Trading Up 1.1%What's Next? - MarketBeat
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key - openPR.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Decliners Report: Can Fulcrum Therapeutics Inc maintain sales growthJuly 2025 PreEarnings & High Return Stock Watch Alerts - baoquankhu1.vn
Insider Sell: Robert Gould Sells 15,000 Shares of Fulcrum Therap - GuruFocus
Sectors Review: Is Fulcrum Therapeutics Inc stock undervalued right nowWeekly Profit Summary & Long-Term Capital Growth Ideas - baoquankhu1.vn
Pharma News: Can Fulcrum Therapeutics Inc maintain sales growthIndex Update & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Can Fulcrum Therapeutics Inc disrupt its industry2025 Support & Resistance & Precise Swing Trade Alerts - baoquankhu1.vn
Can Fulcrum Therapeutics Inc keep up with sector leadersJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Will Fulcrum Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Momentum & Consistent Return Investment Signals - mfd.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Exploring an 82% Potential Upside Amid Clinical Innovations - DirectorsTalk Interviews
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies - Barchart.com
Published on: 2026-01-29 20:30:44 - baoquankhu1.vn
Aug Setups: Will ESNT outperform tech stocksPortfolio Profit Report & Intraday High Probability Alerts - baoquankhu1.vn
Rally Mode: Can Fulcrum Therapeutics Inc. keep up with sector leaders2025 Growth vs Value & AI Driven Stock Reports - baoquankhu1.vn
Trend Report: What is the target price for ALKS stock2025 Year in Review & Fast Gaining Stock Reports - baoquankhu1.vn
Is Fulcrum Therapeutics Inc benefiting from innovation trendsCPI Data & Weekly Top Gainers Trade List - baoquankhu1.vn
Big Money Moves: Can Fulcrum Therapeutics Inc deliver alphaProduct Launch & Safe Entry Momentum Tips - baoquankhu1.vn
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Analyst Calls: Will Fulcrum Therapeutics Inc benefit from seasonality2025 Stock Rankings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Downgrade Watch: Can Fulcrum Therapeutics Inc disrupt its industryQuarterly Portfolio Review & Smart Money Movement Alerts - baoquankhu1.vn
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
IPO Launch: Can Fulcrum Therapeutics Inc deliver alpha2025 Earnings Surprises & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Insider Sell: Is Canadian Imperial Bank of Commerces growth already priced in2025 Stock Rankings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen - MarketBeat
Block Trades: Is Fulcrum Therapeutics Inc part of any ETF2025 Fundamental Recap & Real-Time Volume Triggers - baoquankhu1.vn
Can Fulcrum Therapeutics Inc. disrupt its industryWeekly Trading Summary & Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
Fulcrum Therapeutics (NASDAQ:FULC) Shares Up 7.8%What's Next? - MarketBeat
Whale Trades: Is Fulcrum Therapeutics Inc stock dividend yield sustainable2025 Investor Takeaways & Daily Profit Maximizing Tips - Bộ Nội Vụ
Gains Recap: Whats the fair value of Fulcrum Therapeutics Inc stock2025 Valuation Update & Safe Capital Growth Plans - baoquankhu1.vn
Fulcrum Therapeutics (NASDAQ:FULC) Coverage Initiated by Analysts at JPMorgan Chase & Co. - Defense World
JP Morgan Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight Recommendation - Nasdaq
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap UpShould You Buy? - MarketBeat
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target - marketscreener.com
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock - MSN
Can Fulcrum Therapeutics Inc. stock beat market expectations this quarterFootwear buying guidance for consistent weekly training mileage focuses on stable support and balance, making it a solid option for daily use. - ulpravda.ru
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Market Sentiment & Verified Entry Point Signals - Улправда
Star TribuneFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Can Fulcrum Therapeutics Inc. stock surprise with earnings upside2025 Volume Leaders & Stock Timing and Entry Methods - Улправда
Will Fulcrum Therapeutics Inc. stock outperform Dow Jones indexWeekly Profit Report & Long-Term Capital Growth Strategies - Улправда
How geopolitical tensions affect Fulcrum Therapeutics Inc. stock2025 Biggest Moves & Pattern Based Trade Signal System - Улправда
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionPrice Action & Community Trade Idea Sharing Platform - ulpravda.ru
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: A Biotech With A 90% Upside Potential - DirectorsTalk Interviews
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results - MSN
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Currency Fluctuation Impact & Consistent Triple Returns - Улправда
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):